ARVN logo

Arvinas (ARVN) Company Overview

Profile

Full Name:

Arvinas, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

September 27, 2018

Indexes:

Not included

Description:

Arvinas, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases by discovering, developing, and commercializing treatment methods that target disease-causing proteins. Arvinas utilizes its patented PROTAC Discovery Engine platform. The company was founded in 2015 and is based in New Haven, Connecticut. The therapeutic focus of the issuer includes oncological diseases, neurological disorders, and other serious illnesses. Arvinas, Inc. has two leading product candidates: ARV-110 - for the treatment of men with metastatic castration-resistant prostate cancer ARV-471 - for the treatment of patients with locally advanced or metastatic ER-positive / HER2-negative breast cancer.

Key Details

Price

$19.00

Annual Revenue

$263.40 M(+235.54% YoY)

Annual EPS

-$2.77(+58.16% YoY)

Annual ROE

-32.56%

Beta

1.41

Events Calendar

Earnings

Next earnings date:

Jul 30, 2025

Recent quarterly earnings:

Feb 11, 2025

Recent annual earnings:

Feb 11, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Mar 7, 25 Citigroup
Neutral
Feb 12, 25 Stifel
Buy
Feb 12, 25 Oppenheimer
Outperform
Feb 12, 25 Guggenheim
Buy
Feb 12, 25 BMO Capital
Outperform
Feb 7, 25 Cantor Fitzgerald
Overweight
Feb 3, 25 Barclays
Overweight
Dec 12, 24 Guggenheim
Buy
Dec 11, 24 HC Wainwright & Co.
Buy
Nov 20, 24 BMO Capital
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Arvinas?
  • Does Arvinas pay dividends?
  • What sector is Arvinas in?
  • What industry is Arvinas in?
  • What country is Arvinas based in?
  • When did Arvinas go public?
  • Is Arvinas in the S&P 500?
  • Is Arvinas in the NASDAQ 100?
  • Is Arvinas in the Dow Jones?
  • When was Arvinas's last earnings report?
  • When does Arvinas report earnings?
  • Should I buy Arvinas stock now?

What is the ticker symbol for Arvinas?

The ticker symbol for Arvinas is NASDAQ:ARVN

Does Arvinas pay dividends?

No, Arvinas does not pay dividends

What sector is Arvinas in?

Arvinas is in the Healthcare sector

What industry is Arvinas in?

Arvinas is in the Biotechnology industry

What country is Arvinas based in?

Arvinas is headquartered in United States

When did Arvinas go public?

Arvinas's initial public offering (IPO) was on September 27, 2018

Is Arvinas in the S&P 500?

No, Arvinas is not included in the S&P 500 index

Is Arvinas in the NASDAQ 100?

No, Arvinas is not included in the NASDAQ 100 index

Is Arvinas in the Dow Jones?

No, Arvinas is not included in the Dow Jones index

When was Arvinas's last earnings report?

Arvinas's most recent earnings report was on Feb 11, 2025

When does Arvinas report earnings?

The next expected earnings date for Arvinas is Jul 30, 2025

Should I buy Arvinas stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions